Intramuscular Tranexamic Acid Administration on the Battlefield.

Case Rep Emerg Med

Air Force Special Operations Command, USA.

Published: October 2022

Background: Tranexamic acid (TXA) is routinely administered intravenously (IV) and intraosseously (IO) in response to exsanguination.

Case: This report describes a patient who sustained multiple high-powered rifle gunshot wounds that received battlefield-environment intramuscular (IM) administration of TXA due to inability to obtain IV / IO access. This case represents the unlikely positive outcome in the setting of multiple remarkable obstacles, which may have been ameliorated by novel administration of TXA.

Conclusion: Cases of IM TXA administration as a primary intervention are not well represented in the current body of medical literature. This case report highlights a clinical scenario where IM TXA was utilized as part of first-line treatment that led to a positive clinical outcome. Although IM TXA is not yet endorsed by current trauma guidelines, this case suggests that IM route administration of TXA should be further investigated. If indeed IM administration of TXA proves just as efficacious as alternative routes, this would hold considerable advantageous implications for austere situations were sterility and IV / IO placement are impractical. This would also represent another avenue by which to decrease the time-to-TXA for patients, allowing sooner correction of hemorrhage and trauma-associated coagulopathy.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584727PMC
http://dx.doi.org/10.1155/2022/9689923DOI Listing

Publication Analysis

Top Keywords

administration txa
12
tranexamic acid
8
txa
7
administration
6
intramuscular tranexamic
4
acid administration
4
administration battlefield
4
battlefield background
4
background tranexamic
4
acid txa
4

Similar Publications

Reduction mammaplasty is a common, elective, and safe operation, usually executed in healthy patients. Nonetheless, postoperative complications like bleeding and seroma formation can occur and significantly complicate the postoperative course. Tranexamic acid (TXA), a commonly used antifibrinolytic drug, offers a novel approach to reduce these complications.

View Article and Find Full Text PDF

Background: The relative efficacies of topical and intravenous tranexamic acid (TXA) in spinal surgery remain controversial. This meta-analysis aimed to compare the efficacy and safety of topical versus intravenous TXA in spinal surgery, with a particular focus on the impacts on intraoperative blood loss (IBL) and associated outcomes.

Methods: We searched the PubMed, EMBASE, Medline, and Cochrane Library databases to identify all literature related to topical and intravenous TXA in spinal surgery.

View Article and Find Full Text PDF

The Impact of Tranexamic Acid Administration in Reduction Mammaplasty: A Systematic Review.

Ann Plast Surg

December 2024

Plastic, Reconstructive and Aesthetic Surgery Department and Burn Unit, São João University Hospital, Porto, Portugal.

Background: Previous studies demonstrated the effectiveness and safety of tranexamic acid (TXA) in several surgical specialties. Recent publications suggested that TXA may also be beneficial in plastic surgery, including breast procedures.

Objective: The aim of this study is to evaluate the impact of TXA in reduction mammaplasty by assessing several intraoperative and postoperative outcomes and the safety of its administration.

View Article and Find Full Text PDF

The aim of this study was to test whether there is a necessity for routine postoperative laboratory testing in patients undergoing primary elective unilateral total knee arthroplasty (TKA), with the administration of Tranexamic Acid (TXA) and without the use of tourniquet. : This observational, retrospective cohort study was conducted at Meir Medical Center. The data were collected in 2018-2022.

View Article and Find Full Text PDF
Article Synopsis
  • The study examined the use and safety of intravenous tranexamic acid (TXA) in patients undergoing surgery for intracranial meningiomas, focusing on how different doses affected outcomes.
  • A total of six randomized controlled trials with 881 patients were analyzed, revealing that TXA significantly reduced intraoperative blood loss, blood transfusion rates, surgery duration, and hospital stay lengths, but did not increase postoperative complications.
  • The findings suggested that a preoperative dose of 20 mg/kg with an intraoperative maintenance dose was effective in minimizing blood loss, although further research is needed to confirm these observations and optimize dosing strategies.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!